Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is CRISPR Therapeutics Really Headed to $110?

TheMotleyFool

0 0

Is CRISPR Therapeutics Really Headed to $110?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

CRISPR Therapeutics (NASDAQ: CRSP), once a high flyer due to its cutting-edge, genome-editing solutions, is one of the more unpopular healthcare stocks this week.

That's almost entirely because of the death of one of the patients participating in an early-stage clinical trial for the company's T-cell cancer-treatment candidate, CTX110, which was reported along with the study's results on Wednesday.

Image source: Getty Images.

Source Fool.com

Like: 0

CRSP

Teilen